Ignite Creation Date:
2025-12-24 @ 1:30 PM
Ignite Modification Date:
2025-12-28 @ 4:21 PM
Study NCT ID:
NCT03499795
Status:
COMPLETED
Last Update Posted:
2023-07-14
First Post:
2018-04-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Sponsor:
Inovio Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-15
Start Date Type:
ACTUAL
Primary Completion Date:
2020-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05-26
Completion Date Type:
ACTUAL
First Submit Date:
2018-04-09
First Submit QC Date:
None
Study First Post Date:
2018-04-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-06-12
Results First Submit QC Date:
None
Results First Post Date:
2023-07-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-06-18
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-07-11
Last Update Post Date:
2023-07-14
Last Update Post Date Type:
ACTUAL